NIH Fills Three Institute Director Posts, NIAID Plans Restructuring
NIH announced new directors for NICHD, NLM, and NCCIH, leaving eight institutes without permanent leaders. The NICHD appointment drew criticism due to the candidate's lack of NIH experience and past support for unproven treatments. NIAID released a revised strategic plan and is seeking public comment on a proposed reorganization, while the HBCD study released version 2.1 data.
The NIH's recent appointments highlight a stark contrast in experience. While Peter Embí brings a distinguished background in biomedical informatics and Wendy Weber has climbed the ranks at NCCIH since 2009, John Gaitanis's appointment to NICHD has sparked concern. Critics note his lack of prior NIH funding, peer review, or advisory service, alongside his past advocacy for unproven autism treatments and vaccine skepticism.
Separately, NIAID's proposed restructuring would dissolve its Division of Clinical Research, redistributing its functions across other divisions and creating a new biostatistics office. The institute frames this as aligning with presidential priorities and improving accountability. Meanwhile, researchers can now access version 2.1 data from the HBCD study, a major resource for developmental neuroscience.
The appointment of a NICHD director with unconventional views could influence research funding and public health messaging on pediatric conditions, potentially eroding trust among scientists and families. The NIAID restructuring may streamline or disrupt clinical trial operations, affecting how quickly new treatments reach patients. Meanwhile, the HBCD data release could empower researchers, but its ultimate societal benefit hinges on whether the agency maintains rigorous, evidence-based oversight under its new leadership.